A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma

C Catania Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, ItalyCorrespondence[email protected]

G Pelosi Department of Pathology, European Institute of Oncology Ripamonti 435 Milan, Italy

N Fazio Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

R Biffi Division of Abdomino-Pelvic Surgery, European Institute of Oncology Ripamonti 435 Milan, Italy

G Spitaleri Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

C Noberasco Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

MG Zampino Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

A Maggioni Division of Gynecology, European Institute of Oncology Ripamonti 435 Milan, Italy

G Trifirò Division of Nuclear Medicine, European Institute of Oncology Ripamonti 435 Milan, Italy

F Toffalorio Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

P Della Vigna Divison of Radiology, European Institute of Oncology Ripamonti 435 Milan, Italy

F De Braud Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

T De Pas Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy

show all

References

Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Kaufman HS, Hruban RH, . Adenocarcinoma of the duodenum: Factors influencing long-term survival. J Gastrointest Surg 1998; 2:79–87.
PubMedGoogle Scholar
Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel. Presentation, prognostic factors and outcome of 217 patients. Cancer 2004; 101:518.
PubMed Web of Science ®Google Scholar
Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of duodenum. Am J Surg 1984; 53:23–5.
Google Scholar
Overman MJ, Varadhachari GR, Kopetz S, . Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla di Vater. J Clin Oncol 2009; Feb 23:[Epub ahead of print]
Google Scholar
Suenaga M, Mizunuma N, Chin K, . Chemotherapy for small bowel adenocarcinoma at a single institution. Surg Today 2009; 39:27–31.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date